118 related articles for article (PubMed ID: 2514233)
1. Recombinant human interferon-beta suppresses the replication of HIV and acts synergistically with AZT.
Williams GJ; Colby CB
J Interferon Res; 1989 Dec; 9(6):709-18. PubMed ID: 2514233
[TBL] [Abstract][Full Text] [Related]
2. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.
Crowe SM; McGrath MS; Elbeik T; Kirihara J; Mills J
J Med Virol; 1989 Nov; 29(3):176-80. PubMed ID: 2533247
[TBL] [Abstract][Full Text] [Related]
4. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.
Johnson VA; Barlow MA; Merrill DP; Chou TC; Hirsch MS
J Infect Dis; 1990 Jun; 161(6):1059-67. PubMed ID: 2345291
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
Montefiori DC; Robinson WE; Mitchell WM
AIDS Res Hum Retroviruses; 1989 Apr; 5(2):193-203. PubMed ID: 2469450
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus (HIV)-infected tumor xenografts as an in vivo model for antiviral therapy: role of alpha/beta interferon in restriction of tumor growth in nude mice injected with HIV-infected U937 tumor cells.
Puddu P; Locardi C; Sestili P; Varano F; Petrini C; Modesti A; Masuelli L; Gresser I; Belardelli F
J Virol; 1991 May; 65(5):2245-53. PubMed ID: 1901915
[TBL] [Abstract][Full Text] [Related]
7. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.
Miles SA; Wang HJ; Cortes E; Carden J; Marcus S; Mitsuyasu RT
Ann Intern Med; 1990 Apr; 112(8):582-9. PubMed ID: 2109563
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
Rosenblum MG; Yung WK; Kelleher PJ; Ruzicka F; Steck PA; Borden EC
J Interferon Res; 1990 Apr; 10(2):141-51. PubMed ID: 2140395
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.
Poli G; Orenstein JM; Kinter A; Folks TM; Fauci AS
Science; 1989 May; 244(4904):575-7. PubMed ID: 2470148
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.
Vogt MW; Durno AG; Chou TC; Coleman LA; Paradis TJ; Schooley RT; Kaplan JC; Hirsch MS
J Infect Dis; 1988 Aug; 158(2):378-85. PubMed ID: 2841378
[TBL] [Abstract][Full Text] [Related]
11. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.
Rooke R; Tremblay M; Wainberg MA
Virology; 1990 May; 176(1):205-15. PubMed ID: 1691885
[TBL] [Abstract][Full Text] [Related]
12. Sodium pentosan polysulfate (PPS), an anti-HIV agent also exhibits synergism with AZT, lymphoproliferative activity, and virus enhancement.
Anand R; Nayyar S; Galvin TA; Merril CR; Bigelow LB
AIDS Res Hum Retroviruses; 1990 May; 6(5):679-89. PubMed ID: 1694454
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro.
Nakashima H; Matsui T; Harada S; Kobayashi N; Matsuda A; Ueda T; Yamamoto N
Antimicrob Agents Chemother; 1986 Dec; 30(6):933-7. PubMed ID: 2434024
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant interferon alpha-2a plus 3'-azido-3'-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells.
Darnowski JW; Davol PA; Goulette FA
Biochem Pharmacol; 1997 Feb; 53(4):571-80. PubMed ID: 9105409
[TBL] [Abstract][Full Text] [Related]
15. Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells.
Berman E; Duigou-Osterndorf R; Krown SE; Fanucchi MP; Chou J; Hirsch MS; Clarkson BD; Chou TC
Blood; 1989 Sep; 74(4):1281-6. PubMed ID: 2765664
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
Spector SA; Ripley D; Hsia K
Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
[TBL] [Abstract][Full Text] [Related]
17. Restriction of HIV replication in infected T cells and monocytes by interferon-alpha.
Gendelman HE; Baca L; Turpin JA; Kalter DC; Hansen BD; Orenstein JM; Friedman RM; Meltzer MS
AIDS Res Hum Retroviruses; 1990 Aug; 6(8):1045-9. PubMed ID: 2121192
[TBL] [Abstract][Full Text] [Related]
18. Effect of 3'-azido-2',3'-dideoxythymidine (AZT) and neutralizing antibody on human immunodeficiency virus (HIV)-induced cytopathic effects: implication of giant cell formation for the spread of virus in vivo.
Nakashima H; Tochikura T; Kobayashi N; Matsuda A; Ueda T; Yamamoto N
Virology; 1987 Jul; 159(1):169-73. PubMed ID: 3111083
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.
Hammer SM; Gillis JM
Antimicrob Agents Chemother; 1987 Jul; 31(7):1046-50. PubMed ID: 2444155
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS).
Zeidner NS; Rose LM; Mathiason-DuBard CK; Myles MH; Hill DL; Mullins JI; Hoover EA
J Acquir Immune Defic Syndr (1988); 1990; 3(8):787-96. PubMed ID: 2164083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
